지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 350 - 357 (8page)
이용수
초록· 키워드
오류제보하기
Purpose The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients.
Materials and Methods Fifty-seven Korean patients with advanced GIST who experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off).
Results None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively.
Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31).
Conclusion This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Corless CL / 2002 / KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size / Am J Pathol 160 : 1567 ~ 1572
D'Alessandro R / 2013 / Reversibility of regorafenib effects in hepatocellular carcinoma cells / Cancer Chemother Pharmacol 72 : 869 ~ 877
Debiec-Rychter M / 2005 / Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412inhibitor against imatinib-resistant muta
Demetri GD / 2002 / Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors / N Engl J Med 347 : 472 ~ 480
Demetri GD / 2006 / Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial / Lan
D'Alessandro R / 2013 / Reversibility of regorafenib effects in hepatocellular carcinoma cells / Cancer Chemother Pharmacol 72 : 869 ~ 877
Debiec-Rychter M / 2005 / Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412inhibitor against imatinib-resistant muta
Demetri GD / 2002 / Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors / N Engl J Med 347 : 472 ~ 480
Demetri GD / 2006 / Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial / Lan
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
Yonsei Medical Journal
2024 .07
-
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Clinical and Molecular Hepatology
2020 .01
-
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Cancer Research and Treatment
2022 .10
-
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
Cancer Research and Treatment
2016 .01
-
Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
영남의대학술지
2019 .01
-
Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Cancer Research and Treatment
2015 .01
-
Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
Journal of Liver Cancer
2020 .01
-
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Cancer Research and Treatment
2016 .01
-
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
Journal of Yeungnam Medical Science
2019 .01
-
A rare case of osteonecrosis of the jaw related to imatinib
대한구강악안면외과학회지
2017 .01
-
전이성 위장관 기질종양의 수술 후 완치
Korean Journal of Helicobacter Upper Gastrointestinal Research
2018 .01
-
A case report of successfully treated metachronous gastrointestinal stromal tumor and colon cancer
고신대학교 의과대학 학술지
2023 .03
-
Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
Cancer Research and Treatment
2016 .01
-
Metastatic Cutaneous Duodenal Gastrointestinal Stromal Tumor: A Possible Clue to Multiple Metastases
Annals of Dermatology
2018 .01
-
부신으로 전이된 위장관기질종양 1예
대한내과학회지
2017 .01
-
C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach
Journal of Gastric Cancer
2015 .01
-
Skull Metastasis of Gastric Gastrointestinal Stromal Tumor Successfully Managed by Surgery
대한신경외과학회지
2017 .01
-
An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era
Journal of Liver Cancer
2019 .01
-
Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach
Gut and Liver
2023 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0